Related Experiment Video
Updated: Jun 20, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
The transcriptional regulation of the human CYP2C genes
Yuping Chen1, Joyce A Goldstein
1Laboratory of Pharmacology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Abstract:
In humans, four members of the CYP2C subfamily (CYP2C8, CYP2C9, CYP2C18, and CYP2C19) metabolize more than 20% of all therapeutic drugs as well as a number of endogenous compounds. The CYP2C enzymes are found predominantly in the liver, where they comprise approximately 20% of the total cytochrome P450. A variety of xenobiotics such as phenobarbital, rifampicin, and hyperforin have been shown to induce the transcriptional expression of CYP2C genes in primary human hepatocytes and to increase the metabolism of CYP2C substrates in vivo in man. This induction can result in drug-drug interactions, drug tolerance, and therapeutic failure. Several drug-activated nuclear receptors including CAR, PXR, VDR, and GR recognize drug responsive elements within the 5' flanking promoter region of CYP2C genes to mediate the transcriptional upregulation of these genes in response to xenobiotics and steroids. Other nuclear receptors and transcriptional factors including HNF4alpha, HNF3gamma, C/EBPalpha and more recently RORs, have been reported to regulate the constitutive expression of CYP2C genes in liver. The maximum transcriptional induction of CYP2C genes appears to be achieved through a coordinative cross-talk between drug responsive nuclear receptors, hepatic factors, and coactivators. The transcriptional regulatory mechanisms of the expression of CYP2C genes in extrahepatic tissues has received less study, but these may be altered by perturbations from pathological conditions such as ischemia as well as some of the receptors mentioned above.
Insights
The CYP2C enzyme family significantly impacts drug metabolism and response. Understanding their transcriptional regulation is key to preventing drug interactions and therapeutic failures, especially in the liver.
Area of Science:
- Pharmacology
- Molecular Biology
- Genetics
Background:
- The CYP2C subfamily (CYP2C8, CYP2C9, CYP2C18, CYP2C19) is crucial for metabolizing over 20% of therapeutic drugs and endogenous compounds.
- These enzymes constitute about 20% of hepatic cytochrome P450, playing a dominant role in liver metabolism.
- Induction of CYP2C genes by xenobiotics can lead to drug interactions, tolerance, and treatment failure.
Purpose of the Study:
- To elucidate the transcriptional regulatory mechanisms governing CYP2C gene expression in humans.
- To identify the key nuclear receptors and transcription factors involved in both constitutive and induced expression of CYP2C genes.
- To explore the regulation of CYP2C genes in extrahepatic tissues and potential alterations in pathological conditions.
Main Methods:
- Analysis of transcriptional induction of CYP2C genes in primary human hepatocytes.
- Identification of drug-responsive elements (DREs) in the 5' flanking promoter regions of CYP2C genes.
- Investigation of the roles of various nuclear receptors (CAR, PXR, VDR, GR) and hepatic factors (HNF4α, HNF3γ, C/EBPα, RORs) in CYP2C gene regulation.
Main Results:
- Xenobiotics like phenobarbital, rifampicin, and hyperforin induce CYP2C gene expression and substrate metabolism.
- Drug-activated nuclear receptors (CAR, PXR, VDR, GR) mediate xenobiotic-induced upregulation via DREs.
- Constitutive expression is regulated by hepatic factors including HNF4α, HNF3γ, C/EBPα, and RORs.
- Optimal induction involves cross-talk between xenobiotic receptors, hepatic factors, and coactivators.
Conclusions:
- Transcriptional regulation of CYP2C genes is complex, involving multiple nuclear receptors and hepatic factors.
- Coordinated interactions are essential for achieving maximal CYP2C gene induction.
- Extrahepatic CYP2C gene regulation is less understood but may be influenced by pathological states like ischemia.
More Related Videos
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Master Transcription Regulators
Master Transcription Regulators
Cis-regulatory Sequences
Cis-regulatory Sequences
Cell Specific Gene Expression

